BDSX - Strong Open For This Healthcare Stock

2023-07-12 09:45:46 ET

A medical diagnostics & screening company based out of Boulder, Colorado is causing quite the stir already on Wednesday morning after the company announced “that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.”

While the press release is extremely technical in nature, the bottom line is that traders are excited about it. Shares of %Biodesix (Nasdaq: ) opened up at $1.22/share on Wednesday following the announcement, which was +4.27% above Tuesday’s close.

Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics